The Danish company is using retained agency Biosector2 to handle international medical media relations that will focus on the promotion of the results of clinical trials on NovoSeven’s use for critical bleeding in elective surgery.
Nordisk expects to be able to report from the study of the use of NovoSeven in connection with intra-cerebral haemorrhage in the second half of the year.
Trials are also ongoing into NovoSeven’s efficacy in settings including transplants and trauma.
Trial data could be publicised as early as the fifth World Stroke Congress in Vancouver next month.
Biosector2 European MD Charlotte Ersboell said the potential of the product, which is administered intravenously, was ‘enormous’.
The agency is aiming to raise awareness among the media and doctors of the areas in which the drug could increase treatment options. It reports to Copenhagen-based NovoSeven international marketing manager Kim Jacobsen.
Nordisk continues to use Axon Communications for events and ‘meeting planning’ to promote NovoSeven.
NovoSeven was first developed in the early 1980s and had a staggered licensing in the late 1990s across Europe, North America and Japan for the treatment of bleeding in haemophilia patients with inhibitors.
NovoSeven was approved by the European Commission in January for the control of bleeding in patients with factor VII deficiency and Glanzmann’s thrombasthenia.
Nordisk is a founding client of Biosector2, which has promoted the firm’s diabetes treatments for almost two years.